ABI-2280 is under clinical development by Antiva Biosciences and currently in Phase II for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase II drugs for Cervical Intraepithelial Neoplasia (CIN) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABI-2280’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ABI-2280 overview

ABI-2280 is under development for the treatment of human papillomavirus (HPV) associated cancers such as high-grade squamous intraepithelial neoplasias (HSIL) like cervical intraepithelial neoplasias (CIN 2,3). It is a prodrug of an acyclic nucleoside phosphonate and administered through topical and vaginal routes. It acts by targeting DNA polymerase.

Antiva Biosciences overview

Antiva Biosciences (Antiva) formerly Hera Therapeutics, is a clinical stage bio-pharmaceutical company focused on the development of novel medicines for the treatment of diseases caused by human papillomavirus (HPV) infection. Its lead product candidate ABI-1968, is a double prodrug of an acyclic nucleoside phosphonate which blocks HPV replication and inducing apoptosis in HPV-infected lesions, without affecting normal cells. Antiva is developing additional molecules based on its anti-viral platform targeting HIV infection, the herpes virus, cytomegalovirus, cervical dysplasia, vulvar intraepithelial neoplasia (VIN), among others. The company is funded by Brace Pharma Capital, Canaan Partners, Lumira Capital Corp, and others. Antiva Biosciences is headquartered in South San Francisco, California, the US.

For a complete picture of ABI-2280’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.